Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was to investigate the incidence and outcome of early alanine aminotransferase (ALT) flare in treatment-naive patients with CHB during long-term TDF monotherapy. Methods: One hundred eighty-one treatment-naive CHB patients were treated with a 300-mg once-daily dose of TDF for more than 12 weeks. Virological markers of hepatitis B virus (HBV) and biochemical data were measured at baseline and every 4-12 weeks during the therapy. The proportion of patients with undetectable HBV DNA level (< 100 copies/mL) was noted. Results: The median age was 48.3 years and 122 patients (67.4%) were men. Hepatitis B envelope antigen (HBeAg) was positive in 101 patients (55.8%). No patient had cirrhosis. The median follow-up duration was 45 weeks (12-155 weeks). ALT flare (>5 × upper limit of the normal range) occurred in seven patients (3%) without viral breakthrough within the first 8 weeks after the start of TDF monotherapy. Among them, six patients were HBeAg-positive and one patient was HBeAg-negative. All cases of early ALT flares resolved within 4 weeks and virologic response was observed in all patients without interruption or discontinuation of treatment. Conclusions: Continuous TDF monotherapy was effective and safe in treatment-naive patients with CHB who experienced early ALT flares followed by a decrease in HBV DNA level.
Abstract
Background/Aims: Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was to investigate the incidence and outcome of early alanine aminotransferase (ALT) flare in treatment-naive patients with CHB during long-term TDF monotherapy. Methods: One hundred eighty-one treatment-naive CHB patients were treated with a 300-mg once-daily dose of TDF for more than 12 weeks. Virological markers of hepatitis B virus (HBV) and biochemical data were measured at baseline and every 4-12 weeks during the therapy. The proportion of patients with undetectable HBV DNA level (< 100 copies/mL) was noted. Results: The median age was 48.3 years and 122 patients (67.4%) were men. Hepatitis B envelope antigen (HBeAg) was positive in 101 patients (55.8%). No patient had cirrhosis. The median follow-up duration was 45 weeks (12-155 weeks). ALT flare (>5 × upper limit of the normal range) occurred in seven patients (3%) without viral breakthrough within the first 8 weeks after the start of TDF monotherapy. Among them, six patients were HBeAg-positive and one patient was HBeAg-negative. All cases of early ALT flares resolved within 4 weeks and virologic response was observed in all patients without interruption or discontinuation of treatment. Conclusions: Continuous TDF monotherapy was effective and safe in treatment-naive patients with CHB who experienced early ALT flares followed by a decrease in HBV DNA level.
참고문헌 (29)
- Dienstag JL, "Hepatitis B virus infection", N Engl J Med, 359, pp.1486~1500 (2008)
- Lozano R, "Global and regional mortality from 235 causes of death for 20age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2095~2128 (2012)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
- Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
- Buti M, "Sevenyear efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection", Dig Dis Sci, 60, pp.1457~1464 (2015)
- Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901", Expert Opin Drug Saf, 11, pp.361~368 (2012)
- Mauss S, "Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B", J Hepatol, 55, pp.1235~1240 (2011)
- Duarte-Rojo A, "Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B", Therap Adv Gastroenterol, 3, pp.107~119 (2010)
- Lange CM, "Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function", Hepatology, 50, pp.2001~2006 (2009)
- Chang ML, "Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management", J Hepatol, 61, pp.1407~1417 (2014)
- Marcellin P, "Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B", N Engl J Med, 348, pp.808~816 (2003)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B", N Engl J Med, 352, pp.2673~2681 (2005)
- Zeng M, "A doubleblind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B", Hepatology, 44, pp.108~116 (2006)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
- Hou J, "Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial", Hepatology, 47, pp.447~454 (2008)
- Liaw YF, "2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B", Gastroenterology, 136, pp.486~495 (2009)
- Lok AS, "Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology", J Hepatol, 10, pp.29~34 (1990)
- Flink HJ, "Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peginterferon {alpha}-2b therapy", Gut, 54, pp.1604~1609 (2005)
- Chi H, "Flares during long-term entecavir therapy in chronic hepatitis B", J Gastroenterol Hepatol, 31, pp.1882~1887 (2016)
- Boni C, "Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B", J Clin Invest, 102, pp.968~975 (1998)
- Hultgren C, "Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection", Clin Infect Dis, 29, pp.1575~1577 (1999)
- Boni C, "Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B", J Hepatol, 39, pp.595~605 (2003)
- Evans A, "Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion", Hepatology, 48, pp.759~769 (2008)
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- Perrillo RP, "Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease", Gastroenterology, 120, pp.1009~1022 (2001)
- Liaw YF, "Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B", Hepatology, 32, pp.604~609 (2000)